Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 29 2024 - 6:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 29 February 2024, London UK
GSK announces Dr Jeannie Lee to join the Board as Non-Executive
Director
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has
been appointed to the Board of the Company as a Non-Executive
Director. Jeannie will join the Board on 4 March 2024.
Jeannie is currently the Phillip A. Sharp, PhD, Endowed Chair in
Molecular Biology and Acting Chair of the Department of Molecular
Biology at the Massachusetts General Hospital. She is also
Professor of Genetics (and Pathology) at Harvard Medical School.
She is a pioneer in the field of RNA Biology and its application to
drug development and therapeutics. In addition to senior leadership
positions held at both Harvard Medical School and the Massachusetts
General Hospital, Jeannie co-founded Translate Bio and Fulcrum
Therapeutics, two biotech companies specialising in RNA and
epigenetic therapies.
Jeannie is a Member of the National Academy of Sciences, the
National Academy of Medicine, a Harrington Rare Disease Scholar of
the Harrington Discovery Institute, a recipient of the Lurie Prize
from the Foundation for the National Institutes of Health, an
awardee of the Centennial Prize from the Genetics Society of
America, the 2010 Molecular Biology Prize and the 2020 Cozzarelli
Prize from the National Academy of Sciences, U.S.A, and a Fellow of
the American Association for the Advancement of Science. She has
also served on the Board of the Genetics Society of
America.
Commenting on the appointment, Sir Jonathan Symonds, Chair of GSK
said, "I
am delighted to welcome Jeannie to GSK. Her deep expertise in
scientific and medical innovation, including in the field of RNA
biology and epigenetics which are key parts of GSK's R&D
approach, together with her experience in public health, will bring
strong additional perspective to the Board."
Notes:
|
1.
The appointment of Dr Lee was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a diverse
list of candidates who were approached, evaluated and interviewed
against an agreed set of criteria aligned to the Board's target
skills matrix. The Board satisfied itself that Dr Lee had the
experience and time available to carry out the role.
|
|
2.
The Board has determined that Dr Lee is an independent
Non-Executive Director in accordance with the UK Corporate
Governance Code.
|
|
3.
Dr Lee will receive the standard basic fee for a Non-Executive
Director of £118,352 per annum (including travel allowance).
She will also receive fees of £30,000 per annum as a
scientific and medical expert. Dr Lee will be required to build
towards a share ownership requirement of GSK shares in accordance
with the Company's shareholder approved Non-Executive remuneration
policy.
|
|
4.
"Scientific and Medical Expert" - The Board designates
Non-Executive Directors whose expertise or backgrounds as renowned
medical scientists, researchers, or physicians mean that they can
bring scientific or industry expertise to the Board's
deliberations.
|
|
5.
Dr Lee will become a member of the Science and Corporate
Responsibility committees on her appointment.
|
|
6.
Dr Lee does not have a service contract. She has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
7.
There are no further disclosures to be made in respect of Dr Lee's
appointment under Listing Rule 9.6.13R.
|
|
8.
As of 4 March 2024, the Board of GSK will comprise:
|
Sir
Jonathan Symonds
|
Non-Executive
Chair
|
Emma
Walmsley
|
Chief
Executive Officer
|
Julie
Brown
|
Chief
Financial Officer
|
Charles
Bancroft
|
Senior
Independent Non-Executive Director
|
Elizabeth McKee
Anderson
|
Independent
Non-Executive Director
|
Dr Hal
Barron
|
Non-Executive
Director
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
Wendy
Becker
|
Independent
Non-Executive Director
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
Dr
Jeannie Lee
|
Independent
Non-Executive Director
|
Urs
Rohner
|
Independent
Non-Executive Director
|
Dr
Vishal Sikka
|
Independent
Non-Executive Director
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q4 Results for 2023.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: February
29, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024